Zenlabs Ethica
BSE: ZENLABS · Diversified Commercial Services
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenlabs Ethica's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenlabs Ethica Limited is an Indian pharmaceutical company focused on the marketing and distribution of a diverse range of formulations, including tablets, capsules, and injections. The company operates as a specialty healthcare entity serving various therapeutic segments such as anti-infectives, analgesics, and dermatology.
Business Model
The company employs an asset-light business model, leveraging third-party contract manufacturing to produce its pharmaceutical portfolio. It generates revenue through the strategic marketing and distribution of its branded generic products to a wide network of retailers and distributors across India.
Growth Outlook
Growth is driven by the expansion of the company's presence in the generic medicine space and the continued scaling of its distribution network. The focus remains on providing affordable healthcare solutions through its established brand portfolio.
Key Risks
- Third-party dependency. The company's asset-light model relies heavily on external contract manufacturers, exposing it to potential supply chain disruptions or quality control issues.
- Regulatory compliance. The pharmaceutical sector is subject to stringent government regulations and price controls that can impact profit margins.
- Market competition. The Indian generic pharmaceutical market is highly fragmented and competitive, which may exert pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Zenlabs Ethica and 5,000+ companies — free.
Peers · Diversified Commercial Services
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Zenlabs EthicaZENLABS | ₹16 Cr | — | — | — | 3.8% | — | — | -17.3% |
Radiant Cash Management Services LimitedRADIANTCMS | ₹419 Cr | 13.36 | 7.12 | 1.8% | 12.5% | 10.0% | 14.0% | -34.1% |
Kalind LtdKALIND | ₹382 Cr | 0.18 | 8.31 | 29444.4% | 59.0% | 55.4% | 72.3% | -91.9% |
Majestic AutoMAJESAUT | ₹377 Cr | 3.85 | 4.85 | -45.0% | 167.0% | 15.7% | 18.6% | +4.9% |
Dev Accelerator LimitedDEVX | ₹340 Cr | 28.74 | 3.72 | — | 55.5% | 5.5% | 12.8% | — |
Mizzen VenturesMIZVEN | ₹94 Cr | 89.13 | 48.95 | — | 76.2% | 2.2% | 3.7% | -83.7% |
As of Mar 2026
Financials
Zenlabs Ethica
BSE: ZENLABS · Diversified Commercial Services
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Zenlabs Ethica's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Zenlabs Ethica Limited is an Indian pharmaceutical company focused on the marketing and distribution of a diverse range of formulations, including tablets, capsules, and injections. The company operates as a specialty healthcare entity serving various therapeutic segments such as anti-infectives, analgesics, and dermatology.
Business Model
The company employs an asset-light business model, leveraging third-party contract manufacturing to produce its pharmaceutical portfolio. It generates revenue through the strategic marketing and distribution of its branded generic products to a wide network of retailers and distributors across India.
Growth Outlook
Growth is driven by the expansion of the company's presence in the generic medicine space and the continued scaling of its distribution network. The focus remains on providing affordable healthcare solutions through its established brand portfolio.
Key Risks
- Third-party dependency. The company's asset-light model relies heavily on external contract manufacturers, exposing it to potential supply chain disruptions or quality control issues.
- Regulatory compliance. The pharmaceutical sector is subject to stringent government regulations and price controls that can impact profit margins.
- Market competition. The Indian generic pharmaceutical market is highly fragmented and competitive, which may exert pressure on pricing and market share.
Start your research today
Unlock AI insights, financials, peers and live data on Zenlabs Ethica and 5,000+ companies — free.
Peers · Diversified Commercial Services
As of Mar 2026